Open AccessOUP accepted manuscript
Author(s) -
Tea Petrović,
Inês Alves,
Dario Bugada,
Julio Pascual,
Frano Vučković,
Andrea Skelin,
Joana Gaifem,
Judit Villar-García,
Manuel M. Vicente,
Ângela Fernandes,
Adelaide Dias,
Ivan-Christian Kurolt,
Alemka Markotić,
Dragan Primorac,
Adriana Soares,
Luís Malheiro,
Irena TrbojevićAkmačić,
Miguel Abreu,
Rui Sarmento e Castro,
Silvia Bettinelli,
Annapaola Callegaro,
Marco Arosio,
Lorena Sangiorgio,
Luca Lorini,
Xavier Castells,
Juan Pablo Horcajada,
Salomé S. Pinho,
Massimo Allegri,
Clara Barrios,
Gordan Lauc
Publication year - 2020
Publication title -
glycobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.757
H-Index - 128
eISSN - 1460-2423
pISSN - 0959-6658
DOI - 10.1093/glycob/cwaa102
Subject(s) - philosophy
A large variation in the severity of disease symptoms is one of the key open questions in coronavirus disease 2019 (COVID-19) pandemics. The fact that only a small subset of people infected with severe acute respiratory syndrome coronavirus 2 develops severe disease suggests that there have to be some predisposing factors, but biomarkers that reliably predict disease severity have not been found so far. Since overactivation of the immune system is implicated in a severe form of COVID-19 and the immunoglobulin G (IgG) glycosylation is known to be involved in the regulation of different immune processes, we evaluated the association of interindividual variation in IgG N-glycome composition with the severity of COVID-19. The analysis of 166 severe and 167 mild cases from hospitals in Spain, Italy and Portugal revealed statistically significant differences in the composition of the IgG N-glycome. The most notable difference was the decrease in bisecting N-acetylglucosamine in severe patients from all three cohorts. IgG galactosylation was also lower in severe cases in all cohorts, but the difference in galactosylation was not statistically significant after correction for multiple testing.